U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752875) titled 'A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation' on July 14.
Brief Summary: This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Small Cell Lung Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
Esophageal Cancer
Breast Cancer
Endometrial Cancer
Head and Neck Cancer
Pancreatic Cancer
Locally Advanced Unresectabl...